Bortezomib
| Generic name | Bortezomib |
| Pronunciation | bor-TEZ-oh-mib |
| Brand name(s), other common name(s) | Velcade® |
| Drug type | Proteasome inhibitor |
| How the drug is given | Intravenously (IV) or subcutaneous injection (SC) |
Bortezomib is FDA approved to treat people who have myeloma and people with mantle cell lymphoma who have received at least one prior therapy.
Side effects needing medical attention:
Black, tarry stools; bleeding gums; blood in urine or stool; blurred vision; body aches or pain; burning, crawling, itching, numbness, prickling, ?pins and needles,? or tingling feelings; chest pain or tightness in chest; chills; confusion; faintness or lightheadedness when getting up from a lying or sitting position suddenly; cough; decreased urination; difficult or labored breathing or shortness of breath; dry mouth; fainting; fever; headache; increase in heart rate; loss of voice; lower back or side pain; nasal or ear congestion or runny nose, sneezing or sore throat; pale skin; painful or difficult urination; painful blisters on trunk of body; pinhead-sized red spots on skin; rapid breathing; sunken eyes; sweating; excessive thirst; troubled breathing with exertion; ulcers, sores or white spots in mouth; unsteadiness or awkwardness; unusual bleeding or bruising; unusual tiredness or weakness; weakness in arms, hands, legs or feet; wheezing.
For information on how to manage the costs of drug therapy, please see Financial Matters and Prescription Drug Coverage, or to speak with an Information Specialist, call (800) 955-4572.
